Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
Clearity Foundation Blog
by taylorpond
1w ago
By Ryan Scott Patients who are heavily pretreated with recurrent low-grade serous ovarian cancer (LGSOC) had high response rates, regardless of the number of prior lines of therapy received, when treated with avutometinib (previously VS-6766) plus defactinib, according to data … Read more The post Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC appeared first on Clearity Foundation ..read more
Visit website
CtDNA Offers Potential Biomarker for PARP Inhibitor Maintenance Therapy in Epithelial Ovarian Cancer
Clearity Foundation Blog
by taylorpond
1w ago
Clearity’s Perspective: At the SGO meeting several presentations described how circulating tumor DNA (ctDNA) may be a new, personalized, sensitive tool to help evaluate treatment de-escalation, monitor minimal residual disease (MRD), and track treatment response in ovarian cancer. The application … Read more The post ctDNA Offers Potential Biomarker for PARP Inhibitor Maintenance Therapy in Epithelial Ovarian Cancer appeared first on Clearity Foundation ..read more
Visit website
Rezatapopt Shows Preliminary Efficacy in TP53 Y220C–Mutated Advanced Ovarian Cancer
Clearity Foundation Blog
by taylorpond
1w ago
By Kristi Rosa Rezatapopt (PC14586) elicited responses with a favorable toxicity profile in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations, according to data from the phase 1/2 PYNNACLE study (NCT04585750) presented at the 2024 SGO Annual … Read more The post Rezatapopt Shows Preliminary Efficacy in TP53 Y220C–Mutated Advanced Ovarian Cancer appeared first on Clearity Foundation ..read more
Visit website
New microbiome insights could help boost immunotherapy for a range of rare cancers
Clearity Foundation Blog
by taylorpond
1M ago
Clearity’s Perspective: Previous research in different types of cancer has suggested that there is a relationship between a cancer patient’s gut microbiota (microorganisms that live in the digestive tract) composition and the response to immune checkpoint inhibitor therapy; however, … Read more The post New microbiome insights could help boost immunotherapy for a range of rare cancers appeared first on Clearity Foundation ..read more
Visit website
Cancer Prevention Strategies Linked to Mortality Reduction in BRCA Carriers
Clearity Foundation Blog
by taylorpond
1M ago
By Mike Basset Risk management strategies including bilateral salpingo-oophorectomy (BSO) for ovarian cancer and MRI surveillance for breast cancer were associated with a significant reduction in mortality for women with BRCA1/2 sequence variations, according to results from two cohort studies … Read more The post Cancer Prevention Strategies Linked to Mortality Reduction in BRCA Carriers appeared first on Clearity Foundation ..read more
Visit website
Study Shows Disparities in Psychosocial Outcomes Among Women With Ovarian Cancer in Rural vs Urban Areas
Clearity Foundation Blog
by taylorpond
1M ago
Clearity’s Perspective: Clearity offers emotional support to people with ovarian cancer and their caregivers through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team … Read more The post Study Shows Disparities in Psychosocial Outcomes Among Women With Ovarian Cancer in Rural vs Urban Areas appeared first on Clearity Foundation ..read more
Visit website
Ursula Matulonis, MD, on Concordance of CA-125 and Radiographic Progression in Ovarian Cancer
Clearity Foundation Blog
by taylorpond
1M ago
By Mark Fuerst About half of patients with platinum-sensitive relapsed ovarian cancer (PSROC) on maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) therapy who showed RECIST progression did not have cancer antigen-125 (CA-125) progression, challenging current guidelines, according to a new study.… Read more The post Ursula Matulonis, MD, on Concordance of CA-125 and Radiographic Progression in Ovarian Cancer appeared first on Clearity Foundation ..read more
Visit website
This Could Be a Strong Weapon for Cancer Pain (or Any Pain)
Clearity Foundation Blog
by taylorpond
1M ago
By Courtney Southwick Exercising for upwards of 30 minutes most days may help relieve pain in patients who’ve been diagnosed with cancer, according to a study of exercise and pain outcomes from more than 60,000 people, including 10,000 with a … Read more The post This Could Be a Strong Weapon for Cancer Pain (or Any Pain) appeared first on Clearity Foundation ..read more
Visit website
Patients and Doctors Push Back Against the Harsh Side Effects of Cancer Drugs — “If the patients are not taking the drug, then it’s not going to work”
Clearity Foundation Blog
by taylorpond
1M ago
By Associated Press. For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. They’ve ignited a movement to radically change … Read more The post Patients and Doctors Push Back Against the Harsh Side Effects of Cancer Drugs <br> <p>— “If the patients are not taking the drug, then it’s not going to work”</p> appeared first on Clearity Foundation ..read more
Visit website
Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.
Clearity Foundation Blog
by taylorpond
1M ago
Clearity’s Perspective: Most drugs are tested and approved to treat cancers based on where in the body the cancer started and the type of tissue from which it developed. Enhertu (Trastuzumab Deruxtecan, T-Dxd), a HER2-targeted antibody drug conjugate (ADC), already … Read more The post Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC <p> A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues ..read more
Visit website

Follow Clearity Foundation Blog on FeedSpot

Continue with Google
Continue with Apple
OR